Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-12-08
2009-02-24
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S263400, C514S274000, C544S244000, C544S276000, C544S277000, C544S312000, C544S313000, C544S314000, C544S317000
Reexamination Certificate
active
07495006
ABSTRACT:
Provided are cyclobutyl nucleosides and methods for their use in treatment of infections including Retroviridae (including HIV), Hepadnaviridae (including HBV), or Flaviviridae (including BVDV and HCV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans.
REFERENCES:
patent: 4855466 (1989-08-01), Zahler et al.
patent: 5126345 (1992-06-01), Slusarchyk et al.
patent: 5130462 (1992-07-01), Slusarchyk et al.
patent: 5166397 (1992-11-01), Narita et al.
patent: 5185459 (1993-02-01), Slusarchyk et al.
patent: 5324730 (1994-06-01), Ichikawa et al.
patent: 2004/0229839 (2004-11-01), Babu et al.
patent: 0330992 (1989-09-01), None
The Merck Manual of Diagnosis and Therapy, Seventeenth Edition, published 1999 by Merck Research Laboratories. Ed. by Beers and Berkow, pp. 1132-1135.
Nishizono et al., “Nucleosides and Nucleotides. 159. Stnyhesis of Thietane Nucleosides Via the Pummerer Reaction as a Key Step” Tetrahedron Letters (1996) vol. 37, No. 42, pp. 7569-7572.
Poizot-Martin et al., “Efficacy and Tolerance of HCV Treatment in HIV-HCV Coinfected Patients: The Potential Interaction of PI Treatment” HIV Clinical Trials (2003) vol. 4, No. 4, pp. 262-268.
Anonymous, “Lubocavir” inAIDSMAP Treatment and Care, (Epublication Jan. 8, 2003) at http://www.aidsmap.com/en/docs/FE221C85-DB10-4E87-804B-BEE0480A0BC8.asp.
Bisacchi, G.S., et al., “Synthesis and antiviral activity of enantiomeric forms of cyclobutyl nucleoside ana-logues,”J. Med. Chem., 34(4):1415-1421 (Apr. 1991).
Dunkle, L.M., et al., “Lobucavir: a promising broad-spectrum antiviral agent,”11thIntl. Conf. AIDS(Van-couver, Canada, Jul. 7-12, 1996) program supplement, p. 20, Abstract No. Th.B.943; provided as Natl. Libr. Med. Gateway abstract, NLM Unique ID No. 9870004.
Hayashi, S., et al., “Cyclobut-A and cyclobut-G, carbocyclic oxetanocin analogs that inhibit the replication of human immunodeficiency virus in T cells and monocytes and macrophages in vitro,” (1990)Antimicrob. Agents Chemother., 34(2):287-294 (Feb. 1990).
Kamiya, N., “The mechanisms of action of antivirals against hepatitis B virus infection,”J. Antimicrob. Chemother., 51(5):1085-1089 (May 2003) (published electronically Apr. 14, 2003).
Lalezari, J., et al., “In vivo anti-CMV activity and safety of oral lobucavir in HIV-infected patients,”4thConf. Retrovir. Oppor. Infect. (Washington, D.C., Jan. 22-26, 1997), Session 31, p. 120, Abstract No. 301; also provided in more legible form as Natl. Libr. Med. Gateway abstract, NLM Unique ID No. 100928314.
Maruyama, T., et al., “Synthesis and antiviral activities of carbocyclic oxetanocin analogues,”Chem. Pharm. Bull. (Tokyo), 38(10):2719-2725 (Oct. 1990).
Hager Michael
Liotta Dennis C.
Mao Shuli
Emory University
Jiang Shaojia Anna
King & Spalding
Olson Eric S
LandOfFree
2′ and 3′-substituted cyclobutyl nucleoside... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2′ and 3′-substituted cyclobutyl nucleoside..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2′ and 3′-substituted cyclobutyl nucleoside... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4058399